WellPrept Patient Education · A guide for adults

Understanding Angiomyolipoma

A scan picked up a spot on your kidney called an angiomyolipoma. It is benign. For most adults it is small, and the plan is a periodic scan to keep an eye on it. Here is what it is and what comes next.

Version 1.0 · May 2026 Medically reviewed · Next review May 2027

Welcome

You probably did not go looking for this. A CT scan or an ultrasound was done for a backache, an ER visit, or a checkup. The report came back with a long word on it: angiomyolipoma. An angiomyolipoma (AML) is a benign kidney growth made of blood vessels, muscle, and fat. It does not spread and it does not turn into cancer over time.

Most AMLs stay small and never cause a symptom. The reason a urologist gets involved is the small chance of bleeding from the tiny blood vessels inside larger lesions. Size is the main driver of that risk.

How to use this guide. Start with Chapter 1 to learn what an AML is. Chapter 4 tells the story of the typical small finding. Chapter 5 is for patients with tuberous sclerosis complex (TSC). Chapter 8 walks through the size-based decision: watch, treat, or wait. Chapter 11 has the warning signs that mean call or come in.

Chapter 01

What is an angiomyolipoma?

An angiomyolipoma, or AML, is a benign growth in the kidney. The name comes from its three building blocks: blood vessels (angio), muscle (myo), and fat (lipoma). It is the most common benign solid mass found in the adult kidney.

Benign, not cancer

An AML is benign. It does not invade other organs or spread, and it does not turn into cancer over time. Many people have one for life and never know it is there.

The reason a urologist gets involved is the tiny blood vessels inside the lesion. Some of those vessels form small weak spots called aneurysms. In larger lesions, those weak spots can bleed. That bleeding risk is the reason size matters.

How common is it?

About 1 to 3 people out of every 1,000 have an AML found on a kidney scan. That is less common than simple kidney cysts. AMLs are about four times more common in women than men. The typical age at diagnosis is 40 to 60. Most are found by accident on a scan done for something else.

Benign
An AML is not cancer. It does not spread or turn into cancer.
1 to 3 / 1,000
Roughly how often AML is seen on a kidney scan done for any reason.
4 to 1
Sporadic AML is about four times more common in women than men.

Two kinds of patients with AML

Almost all AMLs fall into one of two groups. Which group you are in changes the follow-up plan.

  • Sporadic AML. A single AML, usually small, in one kidney. This is the most common situation by far.
  • TSC-AML. AMLs in a person who also has a genetic condition called tuberous sclerosis complex (TSC). These are often multiple, in both kidneys, and tend to grow over time. Chapter 5 covers this group.
!
Plain English

An AML is a benign mix of fat, muscle, and blood vessels in the kidney. It is not cancer and does not turn into cancer. The only thing your urologist watches for is bleeding from larger lesions.

Chapter 02

What it's made of and why that matters

An AML is built from three kinds of tissue mixed together: fat, smooth muscle, and blood vessels. The mix is different from one lesion to the next. Each piece plays a role in how the lesion looks on a scan and how it behaves.

The three building blocks

  • Fat. The same kind of fat that sits under your skin. Fat looks dark on a CT scan. The presence of fat in a kidney mass is the big clue that tells the radiologist it is an AML and not a kidney cancer.
  • Smooth muscle. Spindle-shaped cells that give the lesion bulk.
  • Blood vessels. Often shaped oddly, with thick walls. Some form small aneurysms (weak outpouchings). The aneurysms are the source of any bleeding risk.

Why the fat is good news

Fat is the giveaway. Kidney cancers almost never contain visible fat. When a kidney mass clearly has fat in it on a scan, your urologist can usually call it an AML without a biopsy. Most other kidney masses need tissue to be sure. With a fatty AML, the scan is the answer.

Fat-poor AML: the harder case

A small group of AMLs (about 5 out of 100) have so little fat that the scan cannot tell them apart from a small kidney cancer. These are called fat-poor AMLs. If your scan was unclear, the next step might be an MRI with a special "chemical shift" setting, which can pick up tiny amounts of fat that CT misses. Sometimes a needle biopsy of the lesion is done. Sometimes the lesion is treated as if it were a kidney cancer because that is the safer bet.

!
Plain English

The fat in an AML is the same kind of fat as anywhere else in the body. Kidney cancers do not contain that fat. When the scan shows fat in the lesion, that is almost always all the proof anyone needs that it is benign.

Chapter 03

How an AML is found on imaging

An AML is almost always found by accident. A scan is done for some other reason, and the report mentions a fatty lesion in the kidney. The kind of scan you had decides whether more imaging is needed.

CT scan

A CT scan with and without dye is the most common test. The radiologist looks for fat density inside the lesion. They also note the size, the number of lesions, whether the other kidney has one too, and whether any blood vessels inside the lesion look enlarged into aneurysms. If fat is clearly there, the diagnosis is usually settled right there.

MRI of the kidneys

MRI is the main alternative when CT cannot be used or is unclear. It is helpful when:

  • You cannot have the iodine dye used in CT.
  • The CT was not clear about whether fat is in the lesion.
  • You will be followed for many years and the team wants to limit radiation. This matters most for people with TSC, who will have many scans over a lifetime.
  • You are pregnant.

Ultrasound

An ultrasound often shows an AML as a bright spot in the kidney. It can suggest the diagnosis, but it cannot confirm the fat content the way CT and MRI can. Ultrasound is useful for follow-up size checks once the diagnosis is set.

Kidney biopsy

A small needle biopsy of the lesion is sometimes done when imaging cannot settle the question. This is mostly used for fat-poor AMLs and other cases where the scan cannot rule out a kidney cancer. A biopsy of a clearly fatty AML is not standard and is not needed.

i
Bring to your visit

Bring the scan itself on a disc or in your patient portal, along with the report. Your urologist will want to look at three numbers: the size of the lesion, the size of any aneurysm in it, and whether there are AMLs on the other side.

Chapter 04

The typical small sporadic AML

You feel fine, a scan was done for some other reason, and the report mentioned a small AML in one kidney. Most adults with an AML fit that description.

What this usually means

  • It is benign. It is not cancer and will not turn into cancer.
  • It is almost certainly not affecting how your kidney works.
  • For a lesion under 4 cm with no large aneurysm in it, the plan is to leave it alone and check on it now and then.

How sporadic AML usually behaves

Most sporadic AMLs stay the same size or grow very slowly across years. A smaller number grow over time. Growth tends to be modest. The risk of bleeding goes up with the size of the lesion and with the size of any aneurysms inside it. For a small quiet AML in an adult who is not pregnant and not on a blood thinner, the chance of a problem in any given year is very low.

The watch-and-wait plan

For a small AML, the typical plan looks like this:

  • A repeat scan in 6 to 12 months to confirm the lesion is stable.
  • If it is stable, scans every 1 to 2 years for a while.
  • If it stays stable for several years, the gap between scans gets longer.
  • No activity limits. You can exercise and travel as usual.
+
A common worry, answered

"Watching" can sound like the doctor is not doing anything. For a small AML, watching is the right plan. Removing a tiny benign lesion would mean cutting into a healthy kidney to fix something that probably will never cause a problem. The risk of the surgery would be greater than the risk of the lesion.

Chapter 05

AML in tuberous sclerosis (TSC)

Most adults with an AML do not have tuberous sclerosis. This chapter is for patients who do, and for anyone whose scan shows several AMLs in both kidneys.

What TSC is

Tuberous sclerosis complex (TSC) is a genetic condition. It is caused by a change in one of two genes called TSC1 or TSC2. Those genes normally act as brakes on cell growth. When the brake does not work, benign growths can form in many organs over a lifetime, including the brain, skin, heart, lungs, and kidneys.

Why TSC matters for your kidneys

  • About 8 out of 10 people with TSC develop AMLs over a lifetime.
  • TSC-AMLs are usually multiple. They often show up in both kidneys.
  • They tend to be larger than sporadic AMLs and more likely to grow.
  • They are the leading kidney-related cause of illness in adults with TSC.
  • They are more likely to bleed because they are larger and more vascular.

When to think about TSC

Your urologist may bring up TSC if your scan shows any of the following:

  • More than one AML in either kidney.
  • AMLs in both kidneys.
  • An AML found at a young age, especially under 40.
  • Skin findings like small bumps on the face, light patches, or thickened patches on the back.
  • A past history of seizures or trouble with learning as a child.
  • A family member with TSC.

The TSC workup

If your team thinks you may have tuberous sclerosis (TSC), you are sent to a TSC clinic. There you may see doctors for the brain, skin, kidneys, lungs, and genes. The workup can include a brain MRI, a skin exam, lung tests, an eye exam, and a gene test for TSC1 and TSC2.

A note for women: LAM

About 30 to 40 out of 100 adult women with TSC also develop a lung condition called lymphangioleiomyomatosis (LAM). Many have no symptoms. Some develop slow shortness of breath. A chest CT and lung tests are part of the workup for adult women with TSC.

i
Why this group is different

For TSC patients, the kidney plan runs over a lifetime: scans on a set schedule, sometimes a daily pill (see Chapter 7), and a team that coordinates with your other TSC specialists. TSC-AML care has changed a lot since the FDA approved everolimus in 2012.

Chapter 06

Bleeding and Wunderlich syndrome

The single clinical reason an AML matters is the small chance of bleeding from the blood vessels inside it. Most AMLs never bleed. The ones that do can bleed dramatically.

What "Wunderlich syndrome" is

Wunderlich syndrome is the medical name for sudden, non-injury bleeding into and around the kidney. AML is the most common cause. The bleed can stay inside the lesion, can spread into the space around the kidney, or in serious cases can reach the larger space behind the belly.

What a bleeding AML feels like

  • You get sudden severe pain in the flank or upper belly on one side
  • You feel sick to your stomach or vomit
  • You feel lightheaded or faint (a sign that blood pressure has dropped)
  • Sometimes you see new blood in your urine

What raises the bleeding risk

  • Larger lesion size. The risk goes up clearly above 4 cm and rises further above 8 cm.
  • Aneurysms inside the lesion. Aneurysms larger than 5 mm are a known risk factor. The radiologist looks for these on the report.
  • Pregnancy. Higher blood flow and hormones can push an AML to grow or to bleed. Chapter 8 covers planning around this.
  • Blood thinner medications. The decision to take a blood thinner is usually based on the reason it was prescribed in the first place (an arrhythmia, a clot, a stent). Your AML gets factored in, but it rarely overrides those reasons.
  • TSC-AML. Larger size and more vessels mean a higher baseline bleeding risk.

What happens if an AML does bleed

A bleeding AML is treated in the hospital. The first step is fluids, blood transfusion if needed, and pain control. The main treatment is selective arterial embolization, done by an interventional radiologist. A small catheter is threaded up to the blood vessel feeding the AML, and the vessel is blocked off. This usually stops the bleeding and saves the kidney. Surgery is used only when embolization is not available or does not work.

!
Go to the ER

You get sudden severe pain on the side of a known AML, you see heavy blood in your urine, or you feel lightheaded or faint. Any of these can mean a bleed. Go to the emergency room and tell the team you have a known angiomyolipoma.

Chapter 07

Treatment options at a glance

There are four options for an AML: watch it, embolize it, operate, or shrink it with a daily pill. The right choice depends on size, features inside the lesion, whether you have TSC, and your life circumstances.

Active surveillance

For small AMLs with no warning features, the plan is structured imaging follow-up. A scan at 6 to 12 months after the first finding, then every 1 to 2 years if stable. No medication, no procedure. Chapter 4 covers this in more detail.

Selective arterial embolization (SAE)

An interventional radiologist threads a small catheter through an artery in the groin or wrist up to the blood vessel feeding the AML. They inject material (small particles or coils) to block the flow. The lesion shrinks over weeks to months. Usually a one-night hospital stay. A flu-like feeling called post-embolization syndrome (fever, side pain, fatigue) is common for 3 to 7 days after and is treated with rest and supportive care. Embolization preserves as much of the normal kidney as possible. It can be repeated if needed.

Partial nephrectomy

Surgery to remove the AML and a thin rim of normal kidney around it, while leaving the rest of the kidney behind. Used for select cases where the lesion is large and solid, where embolization is not a good fit, or where the imaging cannot fully rule out a kidney cancer. Most often done with the robot in 2026. (For the mechanics of partial nephrectomy, see the WellPrept Localized Kidney Cancer guide.)

Radical nephrectomy

Removing the whole kidney. Uncommon for AML. Saved for very large lesions that have already destroyed most of the kidney, or anatomy that makes partial nephrectomy unsafe. Generally avoided in TSC because of the chance that the other kidney will need attention later.

mTOR inhibitor medication (everolimus, sirolimus)

A class of daily pills that target the same growth pathway that goes wrong in TSC. Everolimus (brand name Afinitor) was approved by the FDA in 2012 for TSC-related AMLs. AMLs typically shrink by 30 to 50 percent over 6 to 12 months on the medication. The effect is not permanent. When the pill is stopped, the lesion tends to grow back, so most TSC patients take it long-term. Use in sporadic AML is uncommon and is still being studied.

Things that are not standard treatment

  • A biopsy of an AML that clearly has fat (not needed; the scan gives the answer)
  • Radiation therapy
  • Chemotherapy
Chapter 08

Size, features, and the decision to treat

For most patients, the AML decision is not urgent. The size of the lesion guides the plan more than any other single number.

The decision to watch or treat depends mostly on the size of the lesion and what is inside it, especially aneurysms. Symptoms, whether you have TSC, and life events like a planned pregnancy also count. The size cutoffs below are widely used guideposts.

Lesion featuresSporadic AMLTSC-AML
Under 4 cm, no symptoms, no large aneurysmWatch with periodic scansWatch; consider mTOR pill if growing or multiple
4 to 8 cmShared decision. Lean toward treatment if growing, symptomatic, large aneurysm, or planning pregnancy.mTOR pill often the first option
Over 8 cmTreatment usually recommended (embolization first)mTOR pill, embolization, or both
Aneurysm larger than 5 mmLower the bar to treat regardless of overall sizeLower the bar to treat regardless of overall size
Symptoms or a prior bleedTreatTreat

Why 4 cm is the number you keep hearing

4 cm has shown up in study after study as the point where bleeding risk starts to climb in a measurable way. A 3.9 cm AML and a 4.1 cm AML behave almost the same. Plenty of lesions just above 4 cm are still watched, especially if there are no aneurysms inside and the lesion has been stable on prior scans. Above 4 cm means treatment is on the table; it does not mean treatment happens automatically.

The 8 cm line

Above 8 cm, most lesions are treated. The bleeding risk at this size is high enough that watching is usually not the safest plan. Embolization is the most common first step.

Pregnancy and planning

Pregnancy raises the risk that an AML will grow or bleed. If you have a known AML and are planning to get pregnant, especially one over 4 cm or with a visible aneurysm, this is a conversation to have with your urologist before you conceive. Treating the lesion before pregnancy is sometimes the safer plan. An AML found during pregnancy is usually managed without surgery when possible. Bleeding in pregnancy is rare and can be treated.

Chapter 09

Frequently asked questions

?

Is this cancer?

No. An angiomyolipoma is a benign growth made of blood vessels, muscle, and fat. It does not spread and does not turn into cancer. The reason a urologist cares about it is the small chance of bleeding from the vessels inside larger ones.

?

How did the radiologist know it was an AML and not cancer?

Most AMLs contain fat that shows up on a CT or MRI. Kidney cancers almost never contain that kind of fat. The fat is the giveaway. In the small number of cases where the scan does not show enough fat, an MRI, a biopsy, or treatment as if it were cancer may be the next step.

?

How big is mine, and does that matter?

Size is the main driver. Under 4 cm is usually watched. Between 4 and 8 cm is a shared decision based on growth, symptoms, aneurysms inside the lesion, and any plans for pregnancy. Over 8 cm is usually treated. An aneurysm larger than 5 mm inside the lesion can lower the bar to treat at any size.

?

What is the chance my AML will bleed?

For a small AML under 4 cm without a large aneurysm, the chance is low. Risk rises with size and is meaningful enough at 8 cm or more that treatment is usually recommended. Pregnancy and blood thinners both raise the chance.

?

Will it grow?

Most sporadic AMLs grow slowly or not at all. A smaller share grow over time. TSC-AMLs are more likely to grow and often need treatment.

?

Do I have tuberous sclerosis?

Likely not. Most adults with one AML have the sporadic kind. A workup for tuberous sclerosis (TSC) is offered if you have more than one AML, AMLs in both kidneys, an AML at a young age, certain skin or brain signs, or a family member with TSC.

?

Can I exercise normally?

Yes. For a small AML that is not changing, you do not need to change a thing. For a large one, your urologist may talk with you about high-impact sports like football or martial arts. Most patients with an AML keep exercising as they always have.

?

Can I get pregnant with an AML?

Yes. Pregnancy does raise the bleeding risk, especially for larger lesions. If you have a known AML and are planning pregnancy, bring it up with your urologist first. For larger lesions or lesions with aneurysms, treating before pregnancy is sometimes the safer plan.

?

Will my AML hurt my kidney function?

Almost never. AMLs do not harm the filter part of the kidney. The only times this comes up are with a very large AML that takes over much of the kidney, or a surgery that takes out a lot of normal kidney too.

?

How often will I need scans?

For a small stable sporadic AML, imaging every 1 to 2 years after the first follow-up is typical. For TSC-AML, scans are more often. Your urologist will set a schedule that fits your specific lesion.

Chapter 10

Questions to ask your doctor

Bring this page to your visit. A short list helps the conversation get to the point.

About the diagnosis

  • Did my scan clearly show fat in the lesion?
  • How sure are you that this is an AML and not a fat-poor AML or a kidney cancer?
  • Do I need an MRI or a biopsy to be more sure?

About size and features

  • How big is my lesion in centimeters?
  • Is there an aneurysm inside the lesion? If yes, how big is it?
  • Are there AMLs in my other kidney too?
  • Do any of my features suggest I should be checked for tuberous sclerosis?

About the plan

  • Given my size and features, do you recommend watching or treating?
  • If watching: how often will I have scans, and what type?
  • If treating: which option do you suggest first, and why?
  • If embolization, who would do it and what is the recovery like?

About life events

  • I am planning a pregnancy. Does my AML change anything?
  • I am on a blood thinner (or considering one). How does that change my risk?
  • Are there activities I should avoid?

About the long view

  • What signs should make me call the office?
  • What signs should make me go to the ER?
  • If everything stays stable for years, can the scans space out further?
Chapter 11

When to seek care

Most of the time, an AML is a quiet finding that needs nothing more than a check-in every year or two. The signs below are the ones that need a call or an ER visit.

Call the office

  • You have new flank or back pain on the side of your known AML that is mild but does not go away
  • You see blood in your urine, even once
  • Another doctor sends you a scan result that mentions your AML
  • You are planning a pregnancy, especially if your AML is 4 cm or larger
  • You are starting a new blood thinner for any reason
  • You or a close relative learns they have tuberous sclerosis
!
Go to the ER

You get sudden severe pain in the flank or upper belly on the side of a known AML. You see heavy blood in your urine, especially with clots. You feel lightheaded, faint, or like you might pass out. In the days after an embolization you run a fever over 100.4°F with side pain that goes past the expected flu-like feeling of the first 3 to 7 days. You have TSC and become severely short of breath, which could be lung-related.

What to bring to any urology visit

  • A copy of the scan report that first mentioned the AML
  • The images themselves, on a disc or shared through a patient portal, along with the report
  • A list of all your pills, plus any supplements and blood thinners like daily aspirin
  • Any past procedures on your kidneys
  • Your questions, written down (Chapter 10 has a starter list)
i
A practical tip

If you go to an ER for any reason, mention your AML up front. It helps the team think about your pain in the right way and order the right scan if needed.

Chapter 12

Words to know

A short reference for the terms most often used in scan reports and visits about an AML.

Angiomyolipoma (AML)
A benign growth in the kidney made of blood vessels, smooth muscle, and fat. Not cancer.
Benign
Not cancer. Does not spread to other parts of the body.
Sporadic AML
An AML in a person without an underlying genetic condition. Usually a single small lesion in one kidney.
TSC-AML
An AML in a person with tuberous sclerosis complex. Often multiple, in both kidneys, larger, and more likely to grow.
Tuberous sclerosis complex (TSC)
A genetic condition caused by a change in the TSC1 or TSC2 gene. Causes benign growths in many organs over a lifetime.
Lymphangioleiomyomatosis (LAM)
A lung condition closely tied to TSC. Affects mostly women. Can be silent or cause shortness of breath.
Fat-poor AML
An AML with so little fat that imaging cannot tell it apart from a small kidney cancer. Sometimes needs a biopsy or treatment as if it were cancer.
Aneurysm
A weak outpouching in a blood vessel wall. Aneurysms inside an AML raise the bleeding risk, especially when larger than 5 mm.
Wunderlich syndrome
Sudden, non-injury bleeding into and around the kidney. AML is the most common cause.
Selective arterial embolization (SAE)
A procedure where a small catheter is used to block the blood supply to a specific spot in the kidney. The most common active treatment for AML.
Post-embolization syndrome
A flu-like feeling (fever, side pain, fatigue) common in the first few days after embolization. Usually goes away in 3 to 7 days.
Partial nephrectomy
Surgery that removes the lesion plus a thin rim of normal kidney while leaving the rest of the kidney behind.
Radical nephrectomy
Surgery that removes the whole kidney.
mTOR inhibitor
A class of medications (everolimus, sirolimus) that target the cell growth pathway disrupted in TSC. Can shrink TSC-related AMLs.
Everolimus (Afinitor)
The FDA-approved mTOR inhibitor pill for TSC-related AML.
Active surveillance
A formal plan to watch a lesion with scans on a set schedule rather than treat it. The standard plan for small AMLs.
Sources

Sources and further reading

This guide pulls from up-to-date sources in urology, radiology, and tuberous sclerosis care.

  1. EAU Guidelines on Renal Cell Carcinoma (covers AML management). European Association of Urology. uroweb.org
  2. Bissler JJ et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex (EXIST-2). Lancet 2013. pubmed.ncbi.nlm.nih.gov
  3. FDA approval of everolimus (Afinitor) for TSC-associated AML, 2012. fda.gov
  4. Yamakado K et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiology 2002. pubmed.ncbi.nlm.nih.gov
  5. International Tuberous Sclerosis Complex Consensus surveillance and management recommendations (2021 update). pubmed.ncbi.nlm.nih.gov
  6. StatPearls: Renal Angiomyolipoma. ncbi.nlm.nih.gov
  7. TSC Alliance patient resources. tscalliance.org
  8. LAM Foundation patient resources. thelamfoundation.org
  9. Society of Interventional Radiology patient resources on renal embolization. sirweb.org

About this guide. Always talk through your case with your own urologist. This guide is here to help that talk along, not take its place.

Playing audio...